Characteristics of Norovirus capsid protein-specific CD8⁺ T-Cell responses in previously infected individuals

References

• Ahmed SM, Hall AJ, Robinson AE, et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014 Aug;14(8):725–13. doi: 10.1016/S1473-3099(14)70767-4
   PubMed Web of Science ®Google Scholar
• Ahmed SM, Lopman BA, Levy K, et al. A systematic review and meta-analysis of the global seasonality of norovirus. PLoS One. 2013;8(10):e75922. doi: 10.1371/journal.pone.0075922
   PubMed Web of Science ®Google Scholar
• Ge L, Chen X, Liu J, et al. Genomic and biological characterization of a pandemic norovirus variant GII.4 Sydney 2012. Vir Gen. 2020 Apr;56(2):174–181. doi: 10.1007/s11262-019-01729-0
   PubMed Web of Science ®Google Scholar
• Ozaki K, Matsushima Y, Nagasawa K, et al. Molecular evolution of the protease region in norovirus genogroup II. Front Microbiol. 2019;10:2991. doi: 10.3389/fmicb.2019.02991
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Norovirus vaccine: priorities for future research and development. Front Immunol. 2020;11:1383. doi: 10.3389/fimmu.2020.01383
   PubMed Web of Science ®Google Scholar
• Parra G. Emergence of norovirus strains: A tale of two genes. Virus Evol. 2019;5(2):vez048. doi: 10.1093/ve/vez048
   PubMed Web of Science ®Google Scholar
• Ruis C, Roy S, Brown JR, et al. The emerging GII.P16-GII.4 Sydney 2012 norovirus lineage is circulating worldwide, arose by late-2014 and contains polymerase changes that may increase virus transmission. PLoS One. 2017;12(6):e0179572. doi: 10.1371/journal.pone.0179572
   PubMed Web of Science ®Google Scholar
• Baehner F, Bogaerts H, Goodwin R. Vaccines against norovirus: state of the art trials in children and adults. Clin Microbiol Infect. 2016;22:S136–S139. doi: 10.1016/j.cmi.2015.12.023
   PubMed Web of Science ®Google Scholar
• Kim L, Liebowitz D, Lin K, et al. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight. 2018;3(13). doi: 10.1172/jci.insight.121077
   Web of Science ®Google Scholar
• Wu K, Werner A, Koch M, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 2021;384(15):1468–1470. doi: 10.1056/NEJMc2102179
   PubMed Web of Science ®Google Scholar
• Tarke A, Sidney J, Methot N, et al. Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv [Preprint]. 2021 Mar 1. doi: 10.1101/2021.02.27.433180.
   Google Scholar
• Ford-Siltz LA, Tohma K, Parra GI. Understanding the relationship between norovirus diversity and immunity. Gut Microbes. 2021 Jan-Dec;13(1):1–13. doi: 10.1080/19490976.2021.1900994
   PubMed Web of Science ®Google Scholar
• Tomov VT, Palko O, Lau CW, et al. Differentiation and protective capacity of virus-specific CD8(+) T cells suggest murine norovirus persistence in an immune-privileged enteric niche. Immunity. 2017 Oct 17;47(4):723–738.e5. doi: 10.1016/j.immuni.2017.09.017
   PubMed Web of Science ®Google Scholar
• He R, Hou S, Liu C, et al. Erratum: Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection. Nature. 2016 Oct 19;540(7633):470. doi: 10.1038/nature20107
   PubMed Web of Science ®Google Scholar
• Wu C, Zanker D, Valkenburg S, et al. Systematic identification of immunodominant CD8+ T-cell responses to influenza a virus in HLA-A2 individuals. Proc Natl Acad Sci USA. 2011 May 31;108(22):9178–9183. doi: 10.1073/pnas.1105624108
   PubMed Web of Science ®Google Scholar
• Malm M, Tamminen K, Vesikari T, et al. Norovirus-specific memory T cell responses in adult human donors. Front Microbiol. 2016;7:1570. doi: 10.3389/fmicb.2016.01570
   PubMed Web of Science ®Google Scholar
• Malm M, Vesikari T, Blazevic V. Identification of a first human Norovirus CD8(+) T Cell epitope restricted to HLA-A(*)0201 Allele. Front Immunol. 2018;9:2782. doi: 10.3389/fimmu.2018.02782
   PubMed Web of Science ®Google Scholar
• Malm M, Tamminen K, Vesikari T, et al. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein. Mol Immunol. 2016 Oct;78:27–37. doi: 10.1016/j.molimm.2016.08.009
   PubMed Web of Science ®Google Scholar
• Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020 Nov;21(11):1336–1345. doi: 10.1038/s41590-020-0782-6
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang B, Chen R, et al. Human Norovirus induces aquaporin 1 production by Activating NF-κB signaling pathway. Viruses. 2022 Apr 18;14(4):842. doi: 10.3390/v14040842
   PubMed Web of Science ®Google Scholar
• Lin Y, Fengling L, Lianzhu W, et al. Function of VP2 protein in the stability of the secondary structure of virus-like particles of genogroup II norovirus at different pH levels: function of VP2 protein in the stability of NoV VLPs. J Microbiol. 2014 Nov;52(11):970–975. doi: 10.1007/s12275-014-4323-6
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang M, Shen Z, et al. The coordinating role of the human norovirus minor capsid protein VP2 is essential to functional change and nuclear localization of the major capsid protein VP1. Arch Virol. 2019 Apr;164(4):1173–1180. doi: 10.1007/s00705-019-04192-2
   PubMed Web of Science ®Google Scholar
• Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol. 2022 Apr 13;22(12):751–764. doi: 10.1038/s41577-022-00707-2
   PubMed Web of Science ®Google Scholar
• Sadegh-Nasseri S, Kim A. Selection of immunodominant epitopes during antigen processing is hierarchical. Mol Immunol. 2019 Sep;113:115–119. doi: 10.1016/j.molimm.2018.08.011
   PubMed Web of Science ®Google Scholar
• Huang M, Zhang J, Chen W. FACS isolation of low percentage human antigen-specific CD8(+) T cells based on activation-induced CD3 and CD8 downregulation. J Immunol Methods. 2019 Sep;472:35–43. doi: 10.1016/j.jim.2019.06.013
   PubMed Web of Science ®Google Scholar
• Nguyen AT, Szeto C, Gras S. The pockets guide to HLA class I molecules. Biochem Soc Trans. 2021 Nov 1;49(5):2319–2331. doi: 10.1042/BST20210410
   PubMed Web of Science ®Google Scholar
• Axelsson-Robertson R, Weichold F, Sizemore D, et al. Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses. Immunology. 2010 Apr;129(4):496–505. doi: 10.1111/j.1365-2567.2009.03201.x
   PubMed Web of Science ®Google Scholar
• Hasan AN, Doubrovina E, Sottile R, et al. Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy. Blood Adv. 2022 Aug 23;6(16):4859–4872. doi: 10.1182/bloodadvances.2022007005
   PubMed Web of Science ®Google Scholar
• Molero-Abraham M, Lafuente EM, Flower DR, et al. Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses. Clin Dev Immunol. 2013;2013:601943. doi: 10.1155/2013/601943
   PubMedGoogle Scholar
• Hanajiri R, Sani GM, Saunders D, et al. Generation of Norovirus-specific T cells from human donors with extensive cross-reactivity to variant sequences: implications for immunotherapy. J Infect Dis. 2020 Feb 3;221(4):578–588. doi: 10.1093/infdis/jiz491
   PubMed Web of Science ®Google Scholar